August 15, 2026

Dana-Farber Research News 08.15.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 - 31.

Dana-Farber

August 14, 2026

Updated ASTRO Guideline Reflects a New Era for Radiation Therapy in Pancreatic Cancer

An updated clinical practice guideline from the American Society for Radiation Oncology substantially expands and modernizes recommendations for the use of radiation therapy in pancreatic cancer.

Baptist Health South Florida

August 07, 2026

Roswell Park Only Hospital in Region Offering SBRT for Prostate Cancer

Roswell Park Comprehensive Cancer Center is now offering an innovative approach to treating prostate cancer that provides a more efficient course of radiation therapy and incorporating a spacer to help shield the rectum from unnecessary treatment.

Roswell Park Comprehensive Cancer Center

August 07, 2026

Adrenal Tumor Patients Need the Multidisciplinary Care Roswell Park Provides

Adrenal cortical carcinomas are rare, diagnosed in only one or two people per million annually, but are also more likely to be found at a later state because they are largely asymptomatic.

Roswell Park Comprehensive Cancer Center

August 04, 2026

U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year Dana-Farber Brigham has been recognized for its excellence in caring for people with cancer.

Dana-Farber

August 01, 2026

Dana-Farber Research News 08.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 - 15.

Dana-Farber

July 31, 2026

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Lung cancer care is entering a more precise and increasingly proactive era. While the disease remains a leading cause of cancer mortality, earlier detection through low-dose CT screening, broader use of molecular profiling and rapid advances in targeted therapy and immunotherapy are changing how patients are diagnosed, staged and treated.

Baptist Health South Florida

July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–a...

The ASCO Post

July 24, 2026

Electronic Prior Authorization Requirements for Drugs

The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperabili...

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherap...

The ASCO Post